Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS

U.S. Urology Partners

Nolensville, Tennessee

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there. Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, he founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.

Disclosures:

Speakers Bureau Member: Astellas, Amgen, Pfizer
Advisory Committee Member: Dendreon, Clovis
Consultant: Merck, Invitae, CUSP PharmaTech Consulting, Cellay, Sun Pharmaceutical Industries, Integra Connect
Honorarium Recipient: Dendreon, Clovis, Merck, Invitae, CUSP PharmaTech Consulting, Cellay, Sun Pharmaceutical Industries, Integra Connect

Talks by Raoul S. Concepcion, MD, FACS

AR-V7 Predicts Response in CRPC

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.

Read More

Updates on Upper Tract Urothelial Cancer

Raoul S. Concepcion, MD, FACS, discusses the challenge of managing upper tract urothelial cancer (UTUC) while avoiding overtreatment. Although nephroureterectomy is an appropriate treatment for high grade tumors, urologists should utilize localized therapy and avoid surgery in low-grade UTUC.

Read More

Immunotherapy 101 for the Urologist

Raoul S. Concepcion, MD, summarizes the mechanism of action behind the immune response to cancer. He also provides an update on the current and emerging immunotherapies for cancer treatment, including vaccines, checkpoint inhibitors, CAR T-cell therapies, viral vectors, and adoptive cell therapy.

Read More

Join the GRU Community

- Why Join? -